Figure S1. Structural alignment of 5 different constructs with daclizumab: (A) represents VH-CDR1, (B) VH-CDR2, (C) VH-CDR3, (D) VL-CDR1, (E) VL-CDR2, (F) VL-CDR3. scFv-L1 is depicted in violet, scFv-L2 in blue, scFv-L3 in red, scFv-L4 in green, scFv-L5 in orange, and the native is shown in black.